Speaker Profile
M.D., Ph.D., Ensign Professor of Medicine, Deputy Director, and Chief of Medical Oncology and Hematology, Yale
Biography
Dr. Roy Herbst is a pioneer of personalized medicine and immunotherapy whose goal is to cure lung cancer. He has led Phase I development of multiple targeted agents for non-small cell lung cancer, including gefitinib, axitinib, atezolizumab, and anti-PD1PDL1 therapies. He has helped bring targeted therapy to early-stage disease as the PI of the adjuvant osimertinib study (A DAURA). He co-led MD Anderson's BATTLE-1 effort. He served as the national PI of the SWOG S0819 trial and held the role of founding PI for the NCI Lung Cancer Master Protocol (Lung-MAP, S1400) for a decade. Heis a member of the National Cancer Policy Forum where he organizes National Academy of Medicine meetings focused on policy issues in personalized medicine and tobacco control. He is an elected member of the NCI Thoracic Malignancies Steering Committee and the chair of the American Association for Cancer Research Science Policy and Government Affairs Committee.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
